An experimental vaccine wiped out lung cancer in some patients and slowed its spread in others in a small but promising study, researchers say.
Three patients injected with the vaccine, GVAX, had no recurrence of lung cancer for more than three years afterward, according to the study of 43 people with the most common form of the disease, non-small cell lung cancer.
The vaccine, developed by researchers at Baylor University Medical Center, is years away from reaching the market, if ever. The researchers hope to apply for Food and Drug Administration approval in three years.
Three patients injected with the vaccine, GVAX, had no recurrence of lung cancer for more than three years afterward, according to the study of 43 people with the most common form of the disease, non-small cell lung cancer.
The vaccine, developed by researchers at Baylor University Medical Center, is years away from reaching the market, if ever. The researchers hope to apply for Food and Drug Administration approval in three years.
Comment